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ABSTRACT
AIM: In recent years, the Wnt signalling pathway has been implicated in 
epithelial ovarian cancer and its members have potential as diagnostic, prognostic 
and therapeutic targets. Here we investigated the role of two Wnt receptor tyrosine 
kinases (RTKs), ROR1 and ROR2, and their putative ligand, Wnt5a, in ovarian cancer.
METHODS: Immunohistochemistry for ROR2 was performed in a large patient 
cohort, including benign controls, borderline tumours and epithelial ovarian cancer. 
In addition, siRNA was used to silence ROR1, ROR2 and Wnt5a individually, and 
together, in two ovarian cancer cell lines, and the effects on cell proliferation, 
adhesion, migration and invasion were measured.
RESULTS: ROR2 expression is significantly increased in ovarian cancer patients 
compared to patients with benign disease. In vitro assays showed that silencing 
either receptor inhibits ovarian cancer cell migration and invasion, and concurrently 
silencing both receptors has an even stronger inhibitory effect on proliferation, 
migration and invasion.
CONCLUSIONS: ROR2 expression is increased in epithelial ovarian cancer, and 
silencing ROR2 and its sister receptor ROR1 has a strong inhibitory effect on the ability 
of ovarian cancer cells to proliferate, migrate and invade through an extracellular 
matrix.
INTRODUCTION
In stark contrast to other cancers, such as breast, 
the survival rate for ovarian cancer has not changed 
significantly in the last thirty years. Challenges remain 
in understanding the aetiology of the disease, how to 
detect it early enough for treatment to be effective, and 
how to stop the disease metastasising throughout the 
body. Though research has shown that there are diverse 
molecular subtypes of ovarian cancer, this genetic 
information has largely not yet been translated into 
changes in clinical practice [1–3]. Further research into 
the molecular changes underpinning the disease needs to 
be conducted to identify those key pathways responsible 
for cancer initiation and progression. Furthermore, once 
pathways are identified, specific biomarkers need to be 
pursued and robustly investigated to determine their 
potential as drug targets.
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We, and others have shown that the Wnt signalling 
pathway is one such pathway involved in ovarian 
carcinogenesis, metastasis and drug resistance [4–8]. 
We recently reported that the Wnt ligand, Wnt5a, is 
upregulated in ovarian cancer patients and modelling this 
in vitro leads to increased cell proliferation and migration 
[5]. Wnt5a is known to bind to and signal through 
Frizzled receptors to initiate β-catenin independent Wnt 
signalling, but has also been shown to act as a ligand for 
the previously named “orphan” receptor, ROR2. ROR2 
is a member of the receptor tyrosine kinase superfamily 
and its overexpression has been reported in many human 
cancers over the last few years [9–15], though little has 
been reported as to the downstream signalling cascade.
ROR1, the sister receptor of ROR2, has recently 
emerged as a critical modulator of Epithelial-Mesenchymal 
Transition (EMT) in breast cancer [16, 17]. Recent studies 
have reported a correlation between ROR1 expression 
and poor clinical outcome including relapse and survival 
in ovarian cancer patients [18, 19] and have even linked 
ROR1 to ovarian cancer stem cell migration and growth of 
tumour xenografts [18, 19].
Based on our previous results supporting the 
upregulation of β-catenin independent Wnt signalling in 
ovarian cancer [5, 20], we hypothesised that ROR2 would 
also be upregulated in ovarian cancer patients.
In addition, we also sought to determine the 
therapeutic potential of targeting these receptors by 
performing an extensive suite of in vitro experiments, 
exploring the functional role of ROR2, its sister receptor, 
ROR1 and putative ligand, Wnt5a in ovarian cancer.
These studies have confirmed the importance of 
ROR1 and ROR2 in the Wnt signalling pathway, and 
provided a strong argument for these receptors potential 
as clinical targets.
RESULTS
Expression of ROR2 is increased in epithelial 
ovarian cancer patients compared to benign controls
Tissue sections from ovarian cancer patients had 
a significantly higher expression of ROR2 than tissue 
sections taken from benign controls (Figure 1, Figure 2A, 
p = 0.0017). ROR2 expression was also elevated in tissue 
sections from patients with borderline tumours compared 
to benign controls (Figure 2A, p = 0.017). There was no 
significant difference observed between ROR2 expression 
in borderline tumours and ovarian cancer patients.
ROR2 expression association with 
clinicopathological parameters
No differences in expression of ROR2 were 
observed between the four main subtypes of epithelial 
ovarian cancer: serous, endometrioid, clear cell and 
mucinous (Figure 2B). There was no association between 
ROR2 expression and stage (Figure 2C), yet a trend was 
observed between ROR2 expression and cancer grade. 
Patients with higher grade tumours were more likely to 
exhibit high ROR2 expression (Figure 2D, p = 0.08). 
Individual scores for each parameter are shown in Table 1. 
Seven patients were missing information and 3 patients 
were missing information on grade, and were therefore 
excluded from further analysis.
Expression of ROR2 in epithelial ovarian cancer 
patients and patient survival
From the whole cohort, 120 epithelial ovarian 
cancer patients showed a recurrence of their disease 
and were therefore included in the relapse-free survival 
analysis. No association was observed between ROR2 
expression at time of surgery and relapse-free survival in 
this patient cohort (Supplementary Figure S1A). Similarly, 
no difference in overall survival was observed within the 
critical period of the first few years following diagnosis 
when patients were stratified according to their ROR2 
expression status at surgery. We did observe in our cohort 
over a very long follow-up period of 20 years that those 
patients with good outcomes (defined as surviving past 
5 years diagnosis), lacking ROR2 expression (0) had 
a worse prognosis than those expressing ROR2 (1, 2) 
(Supplementary Figure S1B).
ROR2 regulates ovarian cancer cell migration 
and invasion
The serous ovarian cancer cell line OVCAR3 
was chosen for ROR2 knockdown assays due to its 
expression of both ROR1 and ROR2 at the mRNA and 
protein level. Successful transfection of ROR2 siRNA 
significantly decreased mRNA (Figure 3A, p < 0.05) and 
protein (Figure 3B) levels of ROR2, and had no effect 
on the level of ROR1, as expected. ROR2 knockdown in 
OVCAR3 slightly decreased proliferation however this 
did not reach significance (Figure 3C). ROR2 knockdown 
had no effect on cell adhesion to collagen or fibronectin 
(Figure 3D). ROR2 knockdown in OVCAR3 significantly 
decreased cell migration in the two-dimensional (2D) 
wound healing assay (Figure 3E, p < 0.05). Control cells 
migrated to completely close the wound within 24 hours, 
whereas ROR2 knockdown cells were unable to close the 
wound, leaving visible space (quantitated as “open image 
area”). To validate the findings from the wound healing 
assay and investigate the role of ROR2 in migration 
further, a three-dimensional (3D) transwell model was 
used, which measured the ability of the cells to migrate 
through pores to a chemoattractant. ROR2 knockdown 
significantly inhibited the ability of OVCAR3 to migrate 
through the transwell (Figure 3F, p < 0.01). To continue 
the investigation into cell invasion, a similar approach 
Oncotarget40312www.impactjournals.com/oncotarget
Figure 1: ROR2 protein expression as measured by immunohistochemistry. A. Representative staining at 0, 1, 2 and 3 
intensity. B. Representative IHC staining in tubal epithelium, ovarian surface epithelium (OSE), cystadenoma, borderline, and ovarian 
cancer samples.
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was used with pre-coated transwells, measuring the ability 
of the cells to invade through a matrigel layer before 
migrating through pores to a chemoattractant. ROR2 
knockdown in OVCAR3 decreased invasion significantly 
(Figure 3G–3H, p < 0.01).
To validate these results, a second siRNA targeting 
ROR2, ROR2 siRNA B was transfected into OVCAR3 
cells and was also shown to inhibit cell migration and 
invasion (Supplementary Figure S2).
To further investigate the role of ROR2 in ovarian 
cancer, a third ROR2 knockdown was undertaken in the 
endometrioid ovarian cancer cell line, TOV112D. As well 
as possessing a mutation in β-catenin, this cell line has 
high levels of ROR2 expression and no detectable ROR1 
expression (Supplementary Figure S7A). ROR2 knockdown 
in this cell line also significantly inhibited cell migration 
and seemed to inhibit invasion (Supplementary Figure S3).
ROR1 regulates ovarian cancer migration 
and invasion
Successful transfection of ROR1 siRNA 
significantly decreased mRNA (Figure 4A, p < 0.01) and 
protein (Figure 4B) levels of ROR1, and had no effect on 
the level of ROR2 (Figure 4A–4B) in the OVCAR3 cell 
line. ROR1 knockdown had no effect on cell proliferation 
Figure 2: ROR2 expression is elevated in epithelial ovarian cancer. A. Expression of ROR2 in benign, borderline tumours, 
ovarian cancer, peritoneal cancer and tubal cancer patients, expressed as a percentage of total. B. ROR2 expression in ovarian cancer 
patients stratified by subtype. C. ROR2 expression in ovarian cancer patients stratified by stage. D. ROR2 expression in ovarian cancer 
patients stratified by grade.
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(Figure 4C), nor on cell adhesion to collagen or fibronectin 
(Figure 4D). However, ROR1 knockdown in OVCAR3 
significantly decreased cell migration in both the 2D 
wound healing assay (Figure 4E, p < 0.05) and the 3D 
transwell assay (Figure 4F, p < 0.01). In addition, ROR1 
knockdown significantly inhibited the invasive ability of 
OVCAR3 cells (Figure 4G–4H, p < 0.01).
To validate these results and rule off any off-target 
effects, a second siRNA targeting ROR1, ROR1 siRNA B, 
was transfected into OVCAR3 cells and also shown to inhibit 
cell migration and invasion (Supplementary Figure S4).
It is important to note that our model “normal” 
epithelial ovarian cell line, HOSE6.3, had high 
expression of ROR1 at both the mRNA and protein level 
(Supplementary Figure S5, Supplementary Figure S7A). 
Knocking down ROR1 in these cells (Supplementary 
Figure S5A–5B), had no effect on cell proliferation, 
adhesion or migration (Supplementary Figure S5C–S5E).
ROR1 and ROR2 synergistically regulate 
ovarian cancer migration and invasion
As the OVCAR3 cell line expressed both ROR1 and 
ROR2, we were interested to investigate the synergistic 
effect of ROR1 and ROR2 on cancer cell behaviour. 
Successful co-transfection of ROR1 and ROR2 siRNA 
significantly decreased mRNA (Figure 5A, p < 0.01) and 
protein (Figure 5B) levels of ROR1 and ROR2. Double 
knockdown of ROR1 and ROR2 significantly decreased 
cell proliferation 72 hours after transfection (Figure 
5C p < 0.05), and reduced adhesion to collagen and 
fibronectin, though this did not reach significance (Figure 
5D). Most interestingly, ROR1 and ROR2 knockdown in 
OVCAR3 significantly decreased cell migration in the 
2D wound healing assay (Figure 5E, p < 0.001) and 3D 
transwell migration assays (Figure 5F, p < 0.001). This 
inhibition was stronger than that seen with ROR1 or 
ROR2 knockdown alone. Similarly, this synergistic effect 
was also observed in the transwell invasion (Figure 5G–
5H, p < 0.001) assays, where the double ROR knockdown 
dramatically halted the ability of the OVCAR3 cells to 
invade through a layer of matrigel.
Wnt5a regulates ovarian cancer migration 
and invasion
To investigate mechanisms of ROR signalling in 
the OVCAR3 cell line, the putative ROR ligand, Wnt5a 
was also silenced using siRNA. Successful transfection 
of Wnt5a siRNA significantly decreased mRNA 
Table 1: Patient cohort characteristics
Patient 
samples
Staining intensity Stage Grade
0 1 2 3 1 2 3 4 1 2 3
ALL 426 222 89 113 2
BENIGN
Healthy controls 163 108 21 32 2
INVASIVE / 
NON INVASIVE 
TUMORS
Borderline tumors 49 18 11 20 0
Cancers
 Ovarian cancers 170 68 52 50 0
   Serous 98 34 29 35 0 9 9 55 20 3 23 69
   Endometrioid 25 13 7 5 0 9 4 12 0 7 12 6
   Clear cell 34 14 11 9 0 2 4 20 6 0 6 28
    Transitional 
cell 8 4 4 0 0 2 0 2 4 4 0 4
   Mucinous 3 2 0 1 0 2 0 1 0 1 2 0
   Other 2 1 1 0 0 0 0 2 0 0 0 2
 Peritoneal 31 23 4 4 0
 Tubal 13 5 1 7 0
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Figure 3: Knockdown of ROR2 in serous ovarian cancer cells inhibits cell migration. A. ROR2 is decreased at the mRNA level 
following siRNA (A) induced knockdown in serous ovarian cancer (OVCAR3) cells. No effect on ROR1 mRNA level. qRT-PCR was performed 
in triplicate and normalised to three different housekeeping genes (SDHA, HSPCB, RPL13A). Results represent an average of four experiments. 
Error bars represent the s.d of the mean. **P < 0.01. B. Densitometric analysis of ROR1 and ROR2 protein levels from three separate experiments. 
Representative immunoblots showing ROR2 knockdown at the protein level in OVCAR3 cells. No effect on ROR1 protein level. Top panel: 
ROR1, middle panel: ROR2, bottom panel: α-tubulin. C. Cell proliferation is slightly decreased following ROR2 knockdown in OVCAR3 cells 
over a 48–72 hours period, but not significantly. Results represent the average of three independent experiments. Error bars represent the s.d of 
the mean. D. ROR2 knockdown has no effect on the adhesion of OVCAR3 cells to collagen or fibronectin. Results represent the average of 3 
experiments. E. Cell migration performed using the wound healing assay is significantly decreased following ROR2 knockdown in OVCAR3 
cells. Results represent an average of three experiments. Error bars represent the s.d of the mean. *P < 0.05. F. Relative cell migration performed 
using the transwell migration assay is significantly decreased following ROR2 knockdown in OVCAR3 cells. Results represent an average of three 
experiments. Error bars represent the s.d of the mean. **P < 0.01. G. Relative cell invasion performed using the matrigel pre coated transwell assay 
significantly decreased following ROR2 knockdown in OVCAR3 cells. Results represent the average of three experiments. Error bars represent 
the s.d of the mean. **P < 0.01. H. Representative picture of OVCAR3 cells invading matrigel over 48 hours.
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Figure 4: Knockdown of ROR1 in serous ovarian cancer cells decreases migration. A. ROR1 is decreased at the mRNA level 
following ROR1 siRNA (A) induced knockdown in serous ovarian cancer (OVCAR3) cells. No effect on ROR2 mRNA level. qRT-PCR was 
performed in triplicate and normalised to three different housekeeping genes (SDHA, HSPCB, RPL13A). Results represent an average of three 
experiments. Error bars represent the s.d of the mean. **P < 0.01. B. Densitometric analysis of ROR1 and ROR2 protein levels from three separate 
experiments. Representative immunoblots showing ROR1 knockdown at the protein level in OVCAR3 cells. No effect on ROR2 protein level. 
Top panel: ROR1, middle panel: ROR2, bottom panel: α-tubulin. C. Cell proliferation does not change following ROR1 knockdown in OVCAR3 
cells over a 48–72 hour period. Results represent the average of three independent experiments. Error bars represent the s.d of the mean. D. ROR1 
knockdown has no effect on the adhesion of OVCAR3 cells to collagen or fibronectin. Results represent the average of 3 experiments and error 
bars represent the s.d of the mean. E. Cell migration performed using the wound healing assay decreases following ROR1 knockdown in OVCAR3 
cells. Results represent an average of three experiments. Error bars represent the s.d of the mean. *P < 0.05. F. Relative cell migration performed 
using the transwell migration assay is significantly decreased following ROR1 knockdown in OVCAR3 cells. Results represent an average of three 
experiments. Error bars represent the s.d of the mean. **P < 0.01. G. Relative cell invasion performed using the matrigel pre coated transwell assay 
is significantly decreased following ROR1 knockdown in OVCAR3 cells. Results represent the average of three experiments. Error bars represent 
the s.d of the mean. **P < 0.01. H. Representative picture of OVCAR3 cells invading matrigel over 48 hours.
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Figure 5: Simultaneous knockdown of ROR1 and ROR2 in serous ovarian cancer cells decreases migration and 
proliferation. A. ROR1 and ROR2 are decreased at the mRNA level following siRNA (A) induced knockdown in serous ovarian cancer 
(OVCAR3) cells. qRT-PCR was performed in triplicate and normalised to three different housekeeping genes (SDHA, HSPCB, RPL13A). Results 
represent an average of three experiments. Error bars represent the s.d of the mean. **P < 0.01, *P < 0.05. B. Densitometric analysis of ROR1 and 
ROR2 protein levels from three separate experiments. Representative immunoblots showing ROR1 and ROR2 knockdown at the protein level 
in OVCAR3 cells. Top panel: ROR1, middle panel: ROR2, bottom panel: α-tubulin. C. Cell proliferation decreases following ROR1 and ROR2 
knockdown in OVCAR3 cells over a 48–72 hour period. Results represent the average of three independent experiments. Error bars represent 
the s.d of the mean. *P < 0.05. D. ROR1 and ROR2 knockdown may decrease the adhesion of OVCAR3 cells to collagen or fibronectin, but not 
significantly. Collagen p = 0.115, Fibronectin p = 0.155. Results represent the average of 3 experiments and error bars represent the s.d of the 
mean. E. Cell migration performed using the wound healing assay decreases following ROR1 and ROR2 knockdown in OVCAR3 cells. Results 
represent an average of three experiments. Error bars represent the s.d of the mean. **P < 0.01. F. Relative cell migration performed using the 
transwell migration assay is significantly decreased following ROR1 and ROR2 knockdown in OVCAR3 cells. Results represent an average 
of three experiments. Error bars represent the s.d of the mean. ***P < 0.001. G. Relative cell invasion performed using the matrigel pre coated 
transwell assay is significantly decreased following ROR1 and ROR2 knockdown in OVCAR3 cells. Results represent the average of three 
experiments. Error bars represent the s.d of the mean. ***P < 0.001. H. Representative picture of OVCAR3 cells invading matrigel over 48 hours.
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(Figure 6A, p < 0.01) levels of Wnt5a, and significantly 
decreased cell proliferation 72 hours after transfection 
(Figure 6B p < 0.05). Migration and invasion of OVCAR3 
was also significantly inhibited by Wnt5a knockdown 
(Figure 6C–6E p < 0.05). A luciferase assay was used 
to investigate TCF/LEF transcriptional activity and 
thus the activation of the β-catenin dependent pathway. 
Interestingly there was no change in activity between the 
control and Wnt5a knockdown cells (Figure 6F).
To validate these results and rule out any off-
target effects, a second siRNA targeting Wnt5a, Wnt5a 
siRNA B was transfected into OVCAR3 cells and also 
shown to significantly inhibit cell migration and invasion 
(Supplementary Figure S6).
To further investigate Wnt5a induced β-catenin 
independent signalling through ROR2, a double 
knockdown of Wnt5a and ROR2 was performed on the 
OVCAR3 cells. Successful co transfection was seen at the 
transcriptional level (Figure 7A, p < 0.01 and p < 0.05) 
which resulted in a significant decrease in proliferation at 
72 hours after transfection (Figure 7B, p < 0.05). Double 
ROR2 and Wnt5a silencing in OVCAR3 also resulted 
in significant inhibition of 3D migration and invasion 
(Figure 7C–7E, p < 0.05 and p < 0.001). A slight increase 
in Wnt3a induced β-catenin dependent signalling was 
observed in the double ROR2/Wnt5a silenced OVCAR3 
cells, however interestingly again, we found that there 
was no significant change in β-catenin dependent pathway 
activation (Figure 7F).
ROR1 and ROR2 may regulate separate 
signalling pathways
Both ROR1 and ROR2 have been linked to the 
β-catenin independent Wnt signalling pathway, but little is 
known about the downstream targets of ROR1 and ROR2 
in cancer, and their effect on the β-catenin dependent Wnt 
signalling pathway. We therefore investigated a number 
of key Wnt and EMT related genes in our knockdown 
samples.
Knockdown of ROR2 in OVCAR3 cells resulted 
in a significant increase in the Wnt target, Axin2 
(Supplementary Figure S7B, p < 0.01) and decrease 
in Jnk (Supplementary Figure S7A, p < 0.01), and 
significantly reduced levels of the EMT marker, Vimentin 
(Supplementary Figure S7B, p < 0.05).
Knockdown of ROR1 in OVCAR3 cells significantly 
increased Axin2 mRNA expression (Supplementary Figure 
S7C, p < 0.05) and had no effect on Jnk. No effect on EMT 
markers was observed.
Double knockdown of ROR1 and ROR2 in 
OVCAR3 cells appeared to increase both Axin2 and Jnk 
mRNA expression (Supplementary Figure S7D). The 
effect on EMT markers was mixed, with Twist mRNA 
expression levels significantly increased (Supplementary 
Figure S7D, p < 0.05), no effect on Vimentin, and 
P-cadherin levels significantly decreased (Supplementary 
Figure S7D, p < 0.05).
Knockdown of ROR2 in TOV112D cells resulted in a 
significant decrease in the Wnt targets, Axin2 (Supplementary 
Figure S7A, p < 0.05) and Jnk (Supplementary Figure S7A, p 
< 0.05), and significantly reduced levels of the EMT marker, 
Vimentin (Supplementary Figure S7A, p < 0.05).
The transcriptional levels of the Wnt gatekeeper, 
SFRP4, were also investigated. Knockdown of ROR1 or 
ROR2 alone has no effect on mRNA levels of SFRP4, 
but double knockdown of ROR1 and ROR2 significantly 
increased SFRP4 expression (Supplementary Figure S7D, 
p < 0.05).
DISCUSSION
We have previously shown in a large patient 
cohort that Wnt5a is upregulated in epithelial ovarian 
cancer compared to healthy controls [5]. Here, we have 
shown that the receptor for the Wnt5a ligand, ROR2, 
is also increased in epithelial ovarian cancer patients 
(Figures 1 and 2). No difference was observed between 
different subtypes of ovarian cancer, suggesting that ROR 
signalling is not subtype specific. This aligns with our 
previous results on two other important Wnt genes, SFRP4 
and Wnt5a [5, 20].
ROR2 expression was not associated with relapse 
free survival or overall survival within the first few years 
following diagnosis and surgery. However, our long 
follow-up data (up to 20 years) did indicate that that 
patients lacking ROR2 expression had a shorter overall 
survival compared to patients with ROR2 expression. 
This trend is opposite to that reported of ROR1 in ovarian 
cancer [18], and ROR2 in other tumours, where ROR2 
expression has been associated with worse overall or 
disease specific survival [10, 13, 21]. These studies all 
had significantly shorter follow-up times. Therefore this 
difference may be due to the multiple confounders that 
cannot be controlled for in long-term survival data, or may 
highlight a different function for ROR2 in ovarian cancer. 
It is also important to note that ROR2 IHC is performed on 
samples taken at the time of surgery, and our samples have 
not been stratified into those patients that presented with 
widespread or localised disease. We are now investigating 
ROR2 expression in other ovarian cancer cohorts to see if 
this survival association holds true. If confirmed, it may 
highlight that ROR2 influences migration and invasion at a 
particular time point in oncogenesis, which could be more 
associated with metastasis than primary tumour formation
Recently, two papers have revealed that ROR1 is 
overexpressed in ovarian cancer and can be targeted for 
anti-cancer stem cell therapy in vivo. In a cohort of 100 
ovarian cancer patients, ROR1 was shown to be increased 
and statistically correlated with FIGO stage, tumour grade 
and lymph node metastasis [18]. Additionally, patients 
with high ROR1 expression had poor disease free and 
Oncotarget40319www.impactjournals.com/oncotarget
Figure 6: Knockdown of WNT5A in serous ovarian cancer decreases migration and invasion. A. WNT5A is decreased at the 
mRNA level following siRNA (A) induced knockdown in serous ovarian cancer (OVCAR3) cells. No effect on ROR1 or ROR2 mRNA level. 
qRT-PCR was performed in triplicate and normalised to three different housekeeping genes (SDHA, HSPCB, RPL13A). Results represent 
an average of three experiments. Error bars represent the s.d of the mean. **P < 0.01. B. Cell proliferation decreases following WNT5A 
knockdown in OVCAR3 cells over a 48–72 hour period, however did not come to significance (P = 0.076). Results represent the average of 
three independent experiments. Error bars represent the s.d of the mean. C. Relative cell migration performed using the transwell migration 
assay is significantly decreased following WNT5A knockdown in OVCAR3 cells. Results represent an average of three experiments. Error 
bars represent the s.d of the mean. **P < 0.01. D. Relative cell invasion performed using the matrigel pre coated transwell assay is significantly 
decreased following WNT5A knockdown in OVCAR3 cells. Results represent the average of three experiments. Error bars represent the s.d of 
the mean. **P < 0.01. E. Representative picture of OVCAR3 cells invading matrigel over 48 hours. F. Luciferase assay determined no change 
in β-catenin dependent signalling after WNT5A knockdown in OVCAR3. Relative β-catenin driven transcription activity was calculated as a 
TOP/FOP ratio in triplicate wells. Results represent an average of three experiments. Error bars represent the s.d of the mean.
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Figure 7: Simultaneous knockdown of WNT5A and ROR2 in serous ovarian cancer decreases proliferation, migration and 
invasion. A. WNT5A and ROR2 are decreased at the mRNA level following siRNA (A) induced knockdown in serous ovarian cancer (OVCAR3) 
cells. No effect on ROR1 mRNA level. qRT-PCR was performed in triplicate and normalised to three different housekeeping genes (SDHA, HSPCB, 
RPL13A). Results represent an average of three experiments. Error bars represent the s.d of the mean. *P < 0.05, **P < 0.01. B. Cell proliferation 
decreases following WNT5A and ROR2 knockdown in OVCAR3 cells after 72 hours. Results represent the average of three independent experiments. 
Error bars represent the s.d of the mean. *P < 0.05. C. Relative cell migration performed using the transwell migration assay is significantly decreased 
following WNT5A and ROR2 knockdown in OVCAR3 cells. Results represent an average of three experiments. Error bars represent the s.d of the 
mean. *P < 0.05. D. Relative cell invasion performed using the matrigel pre coated transwell assay is significantly decreased following WNT5A and 
ROR2 knockdown in OVCAR3 cells. Results represent the average of three experiments. Error bars represent the s.d of the mean. ***P < 0.001. 
E. Representative picture of OVCAR3 cells invading matrigel over 48 hours. F. Luciferase assay determined a slight non-significant increase in 
WNT3A stimulated β-catenin dependent signalling after WNT5A and ROR2 knockdown in OVCAR3. Relative β-catenin driven transcription activity 
was calculated as a TOP/FOP ratio in triplicate wells. Results represent an average of three experiments. Error bars represent the s.d of the mean.
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overall survival. A second recent paper confirmed the 
relationship of ROR1 to poor survival in the publically 
available database Gene Expression Omnibus, and also 
found that ovarian cancer cells with high ROR1 expression 
also featured stem cell like gene signatures [19]. The use 
of primary cancer cells and investigations into ovarian 
cancer spheroids and tumourigenesis in vivo supports the 
role of ROR1 in ovarian cancer. Furthermore, the authors 
linked ROR1 with EMT, and showed that their anti-ROR1 
monoclonal antibody inhibited ovarian cancer xenograft 
growth and reduced expression of EMT markers [19].
Our study confirms the role of ROR1 in ovarian 
cancer progression, via our transwell migration and 
invasion assays (Figure 4E–4H and Figure 5E–5H). 
Moreover for the first time our study also includes ROR2, 
and shows that it is also overexpressed in ovarian cancer, 
and may play a role in cancer progression. A very recent 
paper reported that ROR2 is over-expressed in cervical 
cancer and associated with unfavourable prognosis 
and tumour progression [13]. Thus, the combination 
of our results here in ovarian cancer and recent others 
[13, 16, 19], suggests that in gynaecological cancers 
both ROR1 and ROR2 may be over expressed, and 
important for disease progression. It is imperative that 
the relationship of the two receptors is investigated, to 
further elucidate their individual and combined roles in 
the progression and metastasis of disease.
Modulation of ROR1 and ROR2 in vitro highlighted 
distinct roles for each receptor, as well as some synergistic 
effects. It is important to note that though receptor levels 
were significantly reduced, neither receptor was silenced 
completely, and as expected, the efficacy of silencing 
seemed to determine the degree of migration and invasion 
inhibition. Thus, further studies should include stable 
knockdown cell lines through short hairpin RNA (shRNA).
Knockdown of ROR1 had no effect on proliferation 
(Figure 4C, Supplementary Figure S4C), while 
knockdown of ROR2 appeared to decrease proliferation, 
though this was not statistically significant (Figure 3C, 
Supplementary Figure S3C). When both receptors were 
knocked down, proliferation was significantly decreased 
(Figure 5C, p < 0.05). These results suggest that ROR2 
expression may be more important than ROR1 for ovarian 
cancer cell proliferation, but that targeting them together 
may be effective in inhibiting proliferation. To further 
confirm this, Wnt5a ligand knockdown also inhibited 
proliferation (Figure 6B) which suggests that Wnt5a 
mediated signalling through both ROR1 and ROR2 may 
be essential for cell proliferation.
Knockdown of either ROR1 or ROR2 alone had no 
effect on cell adhesion to collagen or fibronectin (Figure 
3D, Figure 4D). Knockdown of both ROR1 and ROR2 
reduced adhesion to both collagen and fibronectin, but 
this did not reach statistical significance (Figure 5D), 
suggesting that the ROR receptors do not play a major 
role in regulating ovarian cancer cell adhesion.
The strongest effects of ROR knockdown were seen 
in the migration and invasion assays. Knocking down 
either receptor significantly inhibited cell migration in 
both 2D and 3D assays (Figure 3E–3F, Figure 4E–4F), and 
knocking down both receptors strengthened this inhibition 
further (Figure 5E–5F, p < 0.001). ROR1 knockdown 
significantly inhibited cell invasion (Figure 4G, p < 0.01), 
as did ROR2 knockdown (Figure 3G, p < 0.05). However, 
knocking down both ROR1 and ROR2, further inhibited 
cell invasion (Figure 5G, p < 0.001). These results support 
the role of ROR1 and ROR2 in governing ovarian cancer 
cell migration and invasion, and suggest that blocking 
these receptors may inhibit cancer progression.
Wnt5a has been demonstrated to bind to both 
ROR1 and ROR2, so we also investigated the effect of 
silencing this β-catenin independent ligand in our cell line 
models. Knockdown of Wnt5a inhibited cell proliferation, 
migration and invasion (Figure 6C–6D, Supplementary 
Figure S6), and this effect was enhanced when ROR2 was 
silenced at the same time (Figure 7).
The exact mode of signalling of ROR1 and ROR2 
has yet to be elucidated, yet our functional results suggest 
that they may be acting in separate pathways to provide 
different outcomes on migration and invasion. Therefore 
we investigated a number of downstream genes involved 
in β-catenin dependent, β-catenin independent and EMT 
signalling (Supplementary Figure S7). It was interesting 
to see that AXIN2, a β-catenin dependent target was 
increased in either ROR1 or ROR2 knockdown, however 
when both receptors where knockdown together, this 
increase became non-significant. JNK, a β-catenin 
independent target, decreased upon ROR2 knockdown 
however did not change in either ROR1 or double 
knockdown, indicating that ROR2 may only signal 
through the PCP pathway, whereas ROR1 may not. 
This can be supported by other studies, where it was 
shown that ROR2 binds to Wnt5a to activate the small 
GTPases RhoA and Rac, and subsequently initiates the Jun 
Terminal Kinase (JNK) pathway by Actin binding protein 
filamin A to regulate cell polarity and migration [22, 23]. 
Additionally, the interaction of ROR2 with Frizzled7 is 
important in Wnt5a induced AP-1 transcription factor 
activation, downstream of Rac1 and JNK [24]. AP-1 is an 
important transcription factor that is able to regulate the 
expression of many genes involved in cellular proliferation 
and survival. It may be through this arm of signalling that 
ROR2 can regulate cell proliferation as seen in our ovarian 
cancer cell line models.
The EMT gene TWIST increased upon ROR2 and 
double ROR1/ROR2 knockdown however ROR1 alone 
had no effect. Additionally, the EMT gene Vimentin 
decreased upon ROR2 and ROR1 single knockdowns, 
but seemed to slightly increase in the double knockdown 
(non-significantly). This may indicate that ROR2 feeds 
more into TWIST regulation than ROR1, and single 
knockdowns may allow for balance in signalling through 
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the alternative ROR receptor, however when both 
receptors are knocked down, regulation is lost.
ROR1 may be involved in this regulation of 
signalling. ROR1 has been shown to also bind to Wnt5a, 
but to activate NF-kB [25], a family of transcription 
factors largely involved in inflammation and identified 
as the important link between the inflammatory 
microenvironment and progression to malignancy [26]. 
Interestingly, ROR1 has also been shown to be a docking 
site to mediate dependent c-Src and EGFR activation, 
leading to downstream targets of PI3K, AKT and 
NFAT signalling [27]. All of these subsequent pathway 
activations lead to cellular changes in proliferation, 
differentiation, migration, survival and metabolism. 
Interestingly, ROR1 has also been shown to translocate 
to the nucleus and act as a transcription factor which 
may explain its role in pathway regulation [28, 29]. 
However, these unique characteristics of ROR1 have not 
been reported in ovarian cancer, and may be specific in 
each cell type, as has been reported for ROR1 and EGFR 
association in lung cancer models [27].
ROR1 and ROR2 may also signal through different 
co-receptors or ligands. ROR2 was shown to signal 
through FZD7 to regulate cell migration through the 
β-catenin independent pathway in mouse fibroblast 
cells [24], but was also shown to signal through FZD2 
in association with LRP5/6 in lung epithelial cells to 
modulate β-catenin dependent signalling. At present, 
ROR1 has only been shown to signal through binding 
with Wnt5a [25]. Our luciferase assay results (Figures 6F 
and 7F) interestingly do not reveal any change in β-catenin 
dependent signalling after Wnt5a or double Wnt5a and 
ROR2 knockdown. This indicates to us that there is a 
complex signalling network in play and that the ROR 
receptors may not feed into one single arm, yet influence 
a number of surrounding networks as discussed. It will 
be important to elucidate the mode in which ROR1 and 
ROR2 signal in epithelial ovarian cancer.
We have shown for the first time that both ROR1 
and ROR2 regulate ovarian cancer cell migration and 
invasion. However, transwell membranes clearly do 
not mimic the complex inflammatory tumour micro 
environment in which ovarian cancer grows. Therefore 
it would be essential to continue further research into 3D 
culture methods and mouse models, to further validate the 
feasibility of therapeutically targeting these receptors. Our 
supplementary results show (Supplementary Figure S5) that 
targeting these receptors may not have effects on normal 
cells, as our ROR1 siRNA transfected HOSE6.3 normal 
cell line resulted in no changes to cellular proliferation, 
adhesion or migration. This indicates an exciting area 
for drug development, as minimal patient side effects 
may be seen, and, for the first time, a monoclonal ROR1 
targeting antibody did not observe any off-target toxicity 
in preclinical studies and is now available in a phase I trial 
for Chronic Lymphocytic Leukemia [30]. Furthermore 
transcriptionally, no Wnt downstream targets were altered 
(Supplementary Figure S7F) in our HOSE6.3 cells. An 
explanation for this may be that the ROR1 receptor in 
normal cell lines may be present in the immature non-
glycosylated form, and in the mature, active form in our 
ovarian cancer cell lines, as seen in a recent study [31].
The molecular changes underpinning ovarian 
cancer and in particular, ovarian cancer progression 
and metastasis, remain understudied. Important large 
scale sequencing projects are beginning to reveal the 
heterogeneity of this disease and confirm the importance 
of signalling pathways, including Wnt signalling. As cell 
surface receptor tyrosine kinases, ROR1 and ROR2 may 
play a key role in regulating this pathway and warrant 
further investigation.
MATERIALS AND METHODS
Patient cohort
Ethics approval was obtained from the Swiss Ethical 
Cantonal Department SPUK (approval #StV06/2006) to 
collect samples from patients at the University Hospital 
Zurich, Switzerland. The total cohort of 426 samples 
included 163 benign, 49 ovarian borderline, 31 peritoneal 
cancers, 13 tubal cancers, and 170 epithelial ovarian 
cancer samples. Clinicopathological data was available 
for this cohort, including survival data. This patient 
cohort and the production of the tissue microarray have 
previously been described in detail [5, 20].
ROR2 immunohistochemistry
A previously published Tissue Microarray was used 
for the immunohistochemistry (IHC) experiments [5, 20]. 
Briefly, 4 μm paraffin sections were deparaffinized. Antigen 
recovery was conducted using CC1 conditioning solution 
(pH 8.0) for 16 minutes. Staining was performed on a 
VENTANA BenchMark XT automated slide-processing 
system (Ventana Medical Systems, Tucson, AZ). Sections 
were then incubated with anti-ROR2 antibody (Sigma 
HPA021868) for 32 minutes. OptiView DAB IHC 
Detection Kit was used according to the manufacturer’s 
recommendations (Ventana Medical Systems, Tucson, 
AZ). Tissue slides were counterstained with Hematoxylin. 
Sections were dehydrated and coverslipped with PERTEX 
(Histolab, Goteborg, Sweden).
Immunostaining was scored by the percentage and 
intensity of cells staining (0–100% of cells stained within one 
core; intensity 0–3+). Scoring was assessed by a gynecologist 
with experience in immunohistochemistry (A.K.), and a 
subset of cases was analysed by two pathologists (F.M, 
E.O). Discrepancies were resolved by consensus. ROR2 
expression from all cores were averaged per patient.
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Cell culture
The ovarian cancer cell lines TOV112D 
(endometrioid subtype) and OVCAR3 (serous subtype), 
and transformed immortalised human ovarian surface 
epithelial cells (HOSE6.3) were obtained from the 
American Type Culture Collection (Manassas, VA, 
USA) and cultured as per ATCC recommendations. 
Briefly, HOSE6.3 was cultured in a 50:50 ratio of 199 
(Sigma): MCDB105 media (Sigma) containing 10% 
fetal calf serum. The OVCAR3 and TOV112D ovarian 
cancer cells were cultured in RPMI and DMEM media 
respectively, both with 10% Fetal Bovine Serum. Media 
was supplemented with penicillin/streptomycin and 
GlutaMAX (Life Technologies). All cells were grown 
in a humidified atmosphere of 5% CO
2
, at 37°C and 
were repeatedly demonstrated to be free of mycoplasma 
contamination.
Transfections were conducted using Lipo-
fectamine2000 according to manufacturer’s specifications 
(Invitrogen, Carlsbad, CA, USA). In all transfection 
experiments, unless otherwise specified, 1 × 106 cells 
were seeded into 6 well plates and serum starved 
overnight. Cells were transfected the following day, 24 
hours after initial seeding. ROR silencing was achieved 
by transfecting cells with 90 pmol of either ROR1 (named 
ROR1 siRNA A, Ambion, Carlsbad, CA, USA #4390824, 
s9755) or ROR2 (named ROR2 siRNA A, Ambion, 
Carlsbad, CA, USA #4390824 s9759) targeting siRNA , 
or negative control scrambled siRNA. Wnt5a silencing 
was achieved by transfecting cells with 90pmol of Wnt5a 
siRNA (Ambion, Carlsbad, CA, USA , #4392420, s14972, 
named Wnt5a siRNA A). To rule out off-target effects, 
additional ROR1, ROR2 and Wnt5a silencers were also 
transfected (Ambion, Carlsbad, CA, USA ROR1 s9756 
named ROR1 siRNA B, ROR2 s9758 named ROR2 siRNA 
B, ROR2 s9760 named ROR2 siRNA C, Wnt5a s14871 
named Wnt5a siRNA B, Wnt5a s14873 named Wnt5a 
siRNA C). The transfection mixture was removed after 6–8 
hours, washed with serum free media and replaced with 
complete media containing 10% FBS. Cells were allowed 
to grow for a further 48 hours and 72 hours, and then 
harvested for RNA and protein extraction respectively. The 
efficiency of ROR and Wnt5a knockdown was confirmed 
by Western blotting and quantitative real time polymerase 
chain reaction (qRT-PCR).
Quantitative real-time reverse transcriptase 
PCR (qRT-PCR)
RNA extraction, cDNA synthesis and qRT-PCR 
were performed as described previously [7]. Samples were 
run in triplicate and normalised against the housekeeping 
genes succinate dehydrogenase complex subunit A 
(SDHA), 90 kDa heat shock protein 1 beta (HSPCB) 
and 60S ribosomal protein L13a (RPL13A) [32]. All 
experiments contained a negative cDNA control (non-
reverse transcriptase reaction) for each sample as well 
as a negative water control. Expression of genes of 
interest was normalised against the geometric mean of 
the three housekeeping genes using the Vandesompele 
normalisation method [33]. Primer sequences are listed in 
Supplementary Table S1.
Immunoblots
Protein lysates were prepared as described 
earlier [4]. Lysates were separated on 8–12% SDS–
polyacrylamide gels and electrically transferred 
onto PVDF membranes (Millipore, Billerica, MA, 
USA). Membranes were blocked for one hour at 
room temperature prior to anti-ROR1 (R&D Systems 
polyclonal Ab #AF2000) or anti-ROR2 (Sigma Prestige 
polyclonal Ab #HPA021868) antibody incubation 
at 4°C overnight. After washing with 0.01% Tris-
buffered saline/Tween (TBS–Tween), membranes 
were incubated in secondary antibody for one hour. 
After further washing with TBS–Tween, membranes 
were developed using an enhanced chemiluminescence 
reagent and analysed using an ImageQuant LAS4000 
(GE Healthcare Life Sciences).
Proliferation assay
Approximately 6–8 hours after transfection, cells 
were trypsinised, counted, and seeded on to a 96 well plate 
in triplicates at a concentration of 1 × 104 cells/mL for 
OVCAR3 and 2 × 104 cells/mL for TOV112D. One column 
of media only was added for background reading. Cells 
were incubated and periodically analysed using the CCK-8 
kit (Dojindo, Rockville USA) according to manufacturer’s 
instructions. Readings were obtained 24, 48 and 72 hours 
after transfection. An increase in absorbance indicated an 
increase in cell number and significance was determined 
using the students paired t test.
Adhesion assay
Tissue culture plates (Nunc) were coated with 
solutions of type I collagen (10 μg/ml) (Sigma-Aldrich), 
fibronectin (5 μg/ ml) (Millipore) or 3% bovine serum 
albumin (BSA) (SigmaAldrich) in phosphate-buffered 
saline (PBS) (Gibco, Carlsbad, CA, USA) and adhesion 
assays performed as described previously [10].
Migration assay (wound healing)
Wound healing was analysed using IBIDI 
Culture-Inserts (IBIDI GmbH, Martinsried, Germany). 
Twenty-four hours after siRNA transfection, cells were 
dissociated from plates using 0.05% (w/v) trypsin and 
seeded into culture-insert plates at a concentration of 
3 × 104 cells per culture well for OVCAR3 and 5 × 104 
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cells per culture well for TOV112D. After further 24 hours 
incubation, culture inserts were removed. Photographs of 
the movement of cells into the scratch area were taken 
every 6–12 hours until scratch area had closed using a 
Leica DMIL microscope (Leica Microsystems, North 
Ryde, NSW, AU). Wound healing was then analysed using 
TScratch software [34].
Migration assay (transwell)
Cell migration was measured using Transwell 
inserts (Corning Life Sciences, Tewksbury, MA) 
according to manufacturer’s instructions. Briefly, 48 
hours following transfection, cells were counted and 
placed in transwell inserts at a concentration of 1 × 105 
cells per insert for OVCAR3 and 2 × 105 cells per insert 
for TOV112D. For the OVCAR3 cells, the transwell 
inserts were coated approximately 12 hours prior to 
assay with type I collagen (10 μg/ml) (Sigma-Aldrich) to 
aid cell adhesion. After 24 hours incubation, cells were 
fixed with 100% methanol and stained with 1% crystal 
violet. The membrane was then removed and mounted 
on a glass slide. Images were taken of four areas of the 
membrane which were then analysed using ImageJ (Java 
Software). An average cell count of the four images was 
then used in statistical analysis, and all experiments were 
repeated in triplicate.
Invasion assay
Cell invasion was measured using matrigel pre-
coated transwell inserts (BioCoat Matrigel Invasion 
Chambers, Corning Life Sciences, Tewksbury, MA) 
according to manufacturer’s instructions. Briefly, 24 
hours following transfection, cells were counted and 
placed in transwell inserts (which were rehydrated with 
SFM for 2 hours prior) at a concentration of 1 × 105 cells 
per insert for OVCAR3 and 4 × 105 cells per insert for 
TOV112D. After 48 hours incubation, cells were fixed 
with 100% methanol and stained with 1% crystal violet. 
The membrane was then removed and mounted on a glass 
slide. Images were taken of four areas of the membrane 
which were then analysed using ImageJ (Java Software). 
An average cell count of the four images was then used 
in statistical analysis and all experiments were repeated 
in triplicate.
Luciferase assay
A Wnt reporter luciferase assay was used to 
determine the effect of ROR2 and Wnt5a knockdown 
on β-catenin mediated TCF/LEF transcription. 24 hours 
after siRNA transfection, cells were trypsinised and plated 
in triplicate wells in a white bottomed 96 well plate at 
6 × 105 cells/ml. They were then left to adhere at 37°C 
whilst luciferase transfection mix was prepared. Cells 
were transfected with either 200 ng of TOP plasmid or 
200 ng of FOP plasmid, in addition to 200ng of Renilla 
plasmid using 3 ul of Lipofectamine (Invitrogen, Carlsbad, 
CA, USA) per well. After 6–8 hours, transfection mix was 
removed and replaced with complete media. Triplicate 
wells were then stimulated with 40 ng/ul of Wnt3a 
(#5036-WN-010/CF R&D Systems, Minneapolis, USA) 
and Wnt5a (#645-WN-010, R&D Systems, Minneapolis, 
USA) alongside an un-stimulated control over night. The 
following day, firefly luciferase and renilla luminescence 
was read using the Dual-Glo Luciferase assay system 
(Promega) on the Glomax 96 Microplate Luminometer 
(Turner Biosystems Instrument, Sunnyvale CA, USA) 
according to the manufacturer’s protocol. Relative 
β-catenin driven transcription activity was calculated as 
a TOP/FOP ratio.
Statistical analysis
In order to compare ROR2 protein expression levels 
between benign and cancer, generalised linear mixed 
effects models were performed (GLMM). These kinds of 
models are suitable for repeated measure data. To simplify 
this analysis, intensities were grouped in < 1 and > = 1. 
Results are presented as p-values of the corresponding 
comparison.
In order to assess the association between ROR2 
expression and clinicopathological parameters, Chi-
square tests were calculated. These tests do not account 
for repeated measure data and are purely exploratory.
In order to examine time to event data (death, 
relapse) Cox-regressions were performed.
This model allows several entries for each subject, 
Details are described in [35]. Evaluations were done using 
R version 3.0.1.
All in vitro experimental results are expressed as 
mean ± standard deviation (SD). To correctly analyse 
statistical significance, an F-test was first used to determine 
equal or unequal data variance (standard deviation) with a 
value of < 0.05 determining unequal variance, and a value 
> 0.05 determining equal variance. If equal variance, a 
student’s t test type 2 was used to determine significance. 
If unequal variance, a student’s t test type 3 was used to 
determine significance. T test values below P < 0.05 were 
considered statistically significant. *P < 0.05, **P < 0.01, 
***P < 0.001.
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